Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intellia Thera CS (NQ: NTLA )

23.25 +0.49 (+2.15%)
Streaming Delayed Price Updated: 10:14 AM EDT, Jul 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Thera CS

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023
Via Benzinga
Analyst Ratings for Intellia Therapeutics
Via Benzinga
2 Cathie Wood Stocks That Have Tripled Since the 2020 Market Crash
Are these stocks still good buys today? 
Via The Motley Fool
7 Cathie Wood Stocks for Your March Buy List
These top Cathie Wood stocks are just now attempting to pivot higher after a miserable outing for much of 2022. 
Via InvestorPlace
Why Is Intellia Therapeutics (NTLA) Stock Up 10% Today?
Huge opportunities also meets unignorable risks 
Via InvestorPlace
Why Intellia Therapeutics Stock Jumped This Week
Intellia Therapeutics landed a historic regulatory nod from the FDA. 
Via The Motley Fool
Intellia Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Stock Market Rally Rebounds Despite Rising Yields; Salesforce, Tesla In Focus: Weekly Review
Many leaders flashed buy signals as the indexes rebounded from support. 
Via Investor's Business Daily
Why Is Intellia Therapeutics Stock Trading Higher Today?
Intellia Therapeutics (NASDAQ: NTLA) shares are trading higher on Thursday after the company announced that the FDA cleared its Investigational New Drug application for NTLA-2002 for the treatment of... 
Via Benzinga
Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing
The FDA made a bold move in the CRISPR gene-editing realm. 
Via Investor's Business Daily
3 More Mid-Cap Biotechs The Street Sees Doubling
According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk. 
Via MarketBeat
Top CRISPR Stocks
CRISPR is a narrow niche of the biotechnology industry, but it could become the fastest growing and most significant of all the biotech businesses. 
Via Talk Markets
Expert Ratings for Intellia Therapeutics
Via Benzinga
The Latest Analyst Ratings for Intellia Therapeutics
Via Benzinga
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
Better Buy: Beam Therapeutics or Intellia Therapeutics?
The two clinical-stage gene-editing companies have good long-term prospects. 
Via The Motley Fool
3 Deeply Undervalued Stocks That Could Double Your Money
These cutting-edge biotech stocks hold tremendous upside potential. 
Via The Motley Fool
3 Cathie Wood Stocks That Could More Than Double in 12 Months, According to Wall Street
These stocks are risky. But they just might deliver huge gains if analysts are right. 
Via The Motley Fool
3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129%
Cathie Wood is bullish about these stocks. And so are Wall Street analysts. 
Via The Motley Fool
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy? 
Via Talk Markets
Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
Via Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve. 
Via InvestorPlace
3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later
Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time. 
Via InvestorPlace
3 Gene Editing Stocks With the Best Long-Term Potential
These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space 
Via InvestorPlace
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The growth-focused money manager is making moves. 
Via The Motley Fool
Stocks That Hit 52-Week Lows On Friday
  Friday saw 23 companies set new 52-week lows. 
Via Benzinga
2 Risky Cathie Wood Stocks to Buy Today And Hold For 5 Years
Both are hoping to use the latest gene editing technology to make the lucrative therapies of tomorrow. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2023
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.